Cleveland Clinic physicians have completed a study that shows leadless pacemakers might be a safer option than traditional transvenous pacemakers.
Glaukos has the potential to extend its lead into the MIGS market with the approval of the iStent inject Trabecular Micro-Bypass System.
Senseonics has received a PMA for the sensor out to 90 days, but plans call for a 180-day version of the device and eventually a version that lasts for a year.
Dexcom could face even more intense pressure in the CGM market now that Senseonics said its Eversense system has approval. The device could provide long-term continuous monitoring for up to three months.
A Massachusetts jury backed Boston Scientific in a product liability case involving two of the company's transvaginal mesh devices.
The private company said the first patient has been treated with its J-Valve TF System for aortic regurgitation.
FDA approved the CustomFlex Artificial Iris made by HumanOptics for adults or children whose iris is completely missing or damaged due to injury, surgery, or a rare genetic disorder.
Pulmonx released positive one-year-results from the LIBERATE pivotal trial of the Zephyr Endobronchial Valve, which shows the study met all primary and secondary endpoints.
StimGuard scores a CE mark for its overactive bladder system and becomes the latest company to have a commercialized product in the neuromodulation space.
Medtronic has initiated a clinical study to see if its Resolute Onyx DES can treat bifurcation lesions, which account for about 20% of all percutaneous coronary interventions.
Ancora Heart said FDA has approved an expansion of the company’s feasibility study to evaluate the AccuCinch Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR).
The TMVR market continues to thrive, but Neovasc is having problems making a significant impact in the promising space, according to its most recent earnings report.
The market for minimally invasive glaucoma surgery devices is expected to pop for the foreseeable future.